Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Breast Neoplasms 5Leukemia 4Recurrence 3Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lung Neoplasms 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioblastoma 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Spinal Cord Neoplasms 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Prostatic Neoplasms 1Prostate Cancer Recurrent 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Osteosarcoma 1Optic Nerve Glioma 1

Interventions

venetoclax 5Dexamethasone 5Cytarabine 3Cyclophosphamide 3Vincristine 2Decitabine 2trametinib 1ruxolitinib 1pegaspargase 1nilotinib 1navitoclax 1merphos 1dexamethasone acetate 1dexamethasone 21-phosphate 1capivasertib 1blinatumomab 1Vorinostat 1Spinal Puncture 1Specimen Handling 1Mitoxantrone 1Methotrexate 1Magnetic Resonance Spectroscopy 1Dasatinib 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × Dasatinib × Clear all
NCT05751044 2025-09-16

HEM-iSMART B

Princess Maxima Center for Pediatric Oncology

Phase 1/2 Recruiting
26 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡